Public Employees Retirement Association of Colorado Sells 496 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Public Employees Retirement Association of Colorado lessened its position in United Therapeutics Co. (NASDAQ:UTHR) by 9.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,776 shares of the biotechnology company’s stock after selling 496 shares during the period. Public Employees Retirement Association of Colorado’s holdings in United Therapeutics were worth $1,521,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Meiji Yasuda Asset Management Co Ltd. lifted its holdings in United Therapeutics by 1.6% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock valued at $652,000 after acquiring an additional 33 shares during the period. ClariVest Asset Management LLC lifted its holdings in United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 42 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its position in shares of United Therapeutics by 14.0% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 42 shares during the period. Access Investment Management LLC increased its stake in shares of United Therapeutics by 0.8% in the second quarter. Access Investment Management LLC now owns 7,265 shares of the biotechnology company’s stock worth $2,314,000 after purchasing an additional 55 shares in the last quarter. Finally, MBM Wealth Consultants LLC increased its stake in shares of United Therapeutics by 2.7% in the first quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company’s stock worth $515,000 after purchasing an additional 59 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $400.00 target price on shares of United Therapeutics in a research note on Thursday, August 1st. LADENBURG THALM/SH SH lowered United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. Wells Fargo & Company lifted their target price on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. TD Cowen boosted their price target on United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Finally, Bank of America cut their price objective on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $357.17.

United Therapeutics Stock Performance

United Therapeutics stock opened at $355.59 on Tuesday. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $366.08. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. The company’s 50-day moving average price is $339.75 and its 200-day moving average price is $292.88. The company has a market cap of $15.77 billion, a PE ratio of 16.81, a price-to-earnings-growth ratio of 1.25 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). The company had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The business’s revenue for the quarter was up 19.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.24 EPS. On average, equities research analysts forecast that United Therapeutics Co. will post 24.86 EPS for the current fiscal year.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $316.62, for a total transaction of $1,139,832.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $41,160.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Martine A. Rothblatt sold 269 shares of United Therapeutics stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at $45,293.30. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $316.62, for a total transaction of $1,139,832.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at $41,160.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 107,056 shares of company stock valued at $35,319,164. 12.50% of the stock is currently owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.